The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 26, 2022

Filed:

Mar. 19, 2019
Applicant:

Eutilex Co., Ltd., Seoul, KR;

Inventors:

Byoung Se Kwon, Seoul, KR;

Kwang-Hui Kim, Seoul, KR;

Young-Ho Kim, Seoul, KR;

Ho-sik Oh, Seoul, KR;

Don-Gil Lee, Seoul, KR;

Seung-Joo Lee, Seoul, KR;

Beom-Kyu Choi, Seoul, KR;

Insoo Park, Seoul, KR;

Chungyong Han, Seoul, KR;

Assignee:

Eutilex Co., Ltd., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); C07K 16/28 (2006.01); G01N 33/574 (2006.01); G01N 33/577 (2006.01); A61K 47/68 (2017.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3061 (2013.01); A61K 47/6829 (2017.08); A61K 47/6867 (2017.08); C07K 16/28 (2013.01); C07K 16/2833 (2013.01); G01N 33/577 (2013.01); G01N 33/57426 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract

Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated.


Find Patent Forward Citations

Loading…